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The incidence of thyroid cancer is increasing, with a concomitant increase in the number of patients with advanced and metastatic
disease. Discoveries regarding the pathogenesis of thyroid cancer have led to the recent development of new therapeutic agents
that are beginning to appear on the market. Many of these new agents are targeted kinase inhibitors primarily aﬀecting oncogenic
kinases (BRAF V600E, RET/PTC) or signaling kinases (VEGFR, PDGFR). Some of these agents report signiﬁcant partial response
rates, while others attain stabilization of disease as their best response. Their impact on survival is unclear. While these agents
target similar pathways, a wide variety of diﬀerences exist regarding eﬃcacy and side eﬀect proﬁle. Current expert opinion advises
that these agents be used only in a speciﬁc subset of patients.
1.Introduction
The incidence of thyroid cancer is increasing at an alarming
rate. In fact, the incidence has more than doubled in the
past ﬁfty years, and it rose approximately 6% per year from
1997 to 2006 [1]. Peak incidence is in the early ﬁfth decade
for women and the late sixth decade for men. It is two to
three times more common in women than in men, though
mortality rates are higher in men. Mortality rates are also
higher in patients with African ethnic heritage [1].
Total thyroidectomy followed by radioactive iodine (131I)
ablation and thyroid hormone suppression of serum TSH
are the mainstay of treatment for diﬀerentiated thyroid
cancer (DTC). While cure is generally attainable in well-
diﬀerentiated thyroid carcinomas (papillary and follicular
subtypes), recurrence occurs in up to 40% of patients [2].
Unfortunately, in a small percentage of patients with thyroid
cancer recurrence, the tumor becomes dediﬀerentiated. It
does not concentrate iodine and thereby becomes unre-
sponsive to (131I) treatment, likely the result of mutational
changes in the sodium-iodine symporter [3]. Such tumor
often shows increased aggressiveness and has a tendency to
metastasize [4, 5].
Patients with medullary thyroid cancer (MTC) are
susceptible to early metastatic disease. Between 20 to 30% of
patients with T1 tumors at the time of diagnosis already have
metastasis to lymph nodes [6]. The mainstay of treatment
for these patients is total thyroidectomy with aggressive
lymph node dissection. For patients with a family history of
MTC or multiple endocrine neoplasia 2A or 2B, prophylactic
thyroidectomy is recommended as soon as possible, even in
patients who are less than one-year-old [6].
Popular treatment options for advanced stages of DTC
and MTC consist of radiotherapy and chemotherapy, which
confer only a modest beneﬁt on tumor burden and
overall survival. Current treatment regimens for advanced
thyroid cancer include bleomycin, doxorubicin, platinum-
containing compounds, or a combination of these agents.
For the most part, they result in minor responses, and their
use is limited by their toxicities. Bleomycin is well known
for its pulmonary toxicity, while doxorubicin can cause
both cardiac arrhythmias and heart failure. Platinum-based
therapies result in neuropathy, nausea, and renal toxicity [7].
However,recentresearchhasshedlightontheunderlying
molecular mechanisms of thyroid cancer and on the role of
oncogenic kinases in metastatic thyroid cancer in particular2 Journal of Thyroid Research
[8]. Given the high incidence of thyroid cancer and its
recently elucidated molecular mechanisms, thyroid cancer
hasbecomeafocusofeﬀortforuseofnewtargetedtherapies,
especiallythenewclassofagentsthatinhibitkinasesinvolved
in signaling, cellular growth, and angiogenesis [8]. Most of
the therapeutic agents being developed actually target both
the oncogenic and the signaling pathways.
2. Overview of the Molecular Pathways of
Thyroid Cancer
Comprehensive studies of mutation pathways in DTC and
MTC have been undertaken in the past two decades [9–
21]. The knowledge gained from these analyses may render
DTC and MTC amenable to designer therapeutics. The most
important ﬁndings center on the discovery of oncogenic
kinases, as well as the elucidation of various signaling
pathway adaptations occurring in malignant cells. Of the
oncogenic kinases, BRAF V600E mutation and RET/PTC
mutations are being targeted as potential pathways for
therapeutic intervention. Both of these mutations have
the potential to activate the mitogen-activated protein
kinase (MAPK) pathway downstream. Therapeutics target-
ing RET/PTC are being developed particularly for use in
MTC. The vascular endothelial growth factor (VEGF) and
platelet-derived growth factor (PDGF) pathways, as well as
the phosphatidylinositol-3-kinase-(PI3K-) phosphatase with
tensin homology (PTEN) pathway are important signaling
cascades being investigated for possible development of
therapeutic kinase inhibitors (Figure 1).
2.1. Oncogenic Kinases. BRAF mutations are the most com-
monly encountered mutation in PTC [13, 22, 23]. BRAF
mutationsarepresentin29–83%ofcasesofpapillarythyroid
cancer (PTC) [8, 24]. Anaplastic thyroid carcinoma (ATC)
also has a high frequency of BRAF mutations, with up to
50% of ATC harboring a mutation in this entity [25]. The
BRAF gene is located on chromosome 7q24. Oncogenic
BRAF mutations in PTC commonly (approximately 80%)
are comprised of a thymidine to adenine substitution in
exon 15 (T1799A) resulting in an amino acid sequence
change of valine to glutamate (V600E) [22, 26]. This change
destabilizes the inactive conformation of BRAF, rendering
it constitutively active [14, 26, 27]. Activated oncogenic
mutant BRAF has a higher aﬃnity for MEK1 and MEK2
and increases the phosphorylation of MEK. BRAF V600E
also potently activates MAPK pathway directly. BRAF can
be activated by another genetic rearrangement leading to
formation of a fusion protein, AKAP9-BRAF, which can
activate MAPK pathways. This rearrangement is present in
approximately11%ofPTC[28].Thebasisofthesemutations
is not known. The BRAF V600E mutant does not seem
related to radiation exposure. In contrast, the AKAP9-BRAF
is thought to be related to irradiation [28–30].
Some authors suggest that PTCs with BRAF mutations
are more aggressive and tend to present at a more advanced
clinicalstageandwithextrathyroidalinvasion[24,31].BRAF
mutations are more frequently present in older patients with
otherwise classical PTC, who are at a more advanced stage
of the disease at the time of diagnosis [24, 31, 32]. This
suggestion is also supported by the observation that the tall-
cell variant of PTC has a high prevalence of BRAF mutations
[33]. Additionally, BRAF mutation is common in aggressive
microcarcinomas [34, 35]. These mutations occur rarely or
not at all in follicular or medullary thyroid carcinomas,
benign adenomas, or benign hyperplasias [23, 36, 37]. Many
undiﬀerentiated and anaplastic carcinomas arising from pre-
existing PTC have BRAF mutations [32, 38]. Additionally,
tumors with BRAF mutations tend to have decreased expres-
sion of NIS symporter, and leading the tumor to become
refractory to radioiodine treatment [39–41]. Interestingly,
BRAF mutation is generally present without other common
mutations found in PTC, suggesting that BRAF mutation
alone may be suﬃcient for tumorigenesis [13, 36, 37].
The oncogenic RET/PTC mutation is also commonly
found in PTCs, approximately 10–50% [21]. Familial forms
of medullary thyroid carcinoma (MTC) also arise from
inheritable activating mutations in RET (the most studied
being the C634R change) [42, 43]. RET/PTC rearrangements
are very common in thyroid tissue exposed to radiation,
and are also commonly noted in pediatric PTC [44, 45].
Radiation has been shown to induce this recombination in
thyroid cell lines and in normal human thyroid tissue trans-
planted onto SCID mice [46]. Twelve forms of RET/PTC
mutations have been described, with forms 1 and 3 being the
most common [16]. RET/PTC1 is typically associated with
classical PTC, while RET/PTC3 rearrangement is associated
with solid-variant PTCs [17]. These mutations result in
the linking of the promoter and N-terminus to unre-
lated C-terminus fragments of RET, leading to a chimeric
receptor that is constitutively active. RET/PTC mutations
are uncommon in poorly diﬀerentiated cancers, suggesting
that this mutation may imply a favorable prognosis [18].
Curiously, RET/PTC expression in thyroid cells has been
found to be associated with impaired hormonogenesis and
hypothyroidism, particularly Hashimoto’s thyroiditis (HT).
Whether or not this predisposes an individual with HT to
thyroid cancer is unclear [47–49].
2.2. Signaling Kinases. A few of the important signaling cas-
cadesbeinginvestigatedforthepossibledevelopmentofther-
apeutic kinase inhibitors are the VEGF and PDGF pathways,
as well as the PI3K/PTEN pathway. VEGF is a proangiogenic
factor that binds to two receptor tyrosine kinases (VEGFR-
1 and VEGFR-2), of which VEGFR-2 is widely recognized to
betheprimarymediatorofangiogenesis.PDGF-Bisrequired
forthematurationofmicrovasculature,whiletumor-derived
PDGF-A recruits angiogenic stroma to the tissue. VEGFR
and PDGFR mutually support the increased activity of each
other [50]. Increased VEGF expression appears to be related
to worse prognosis, increased risk of recurrence, and the
presence of metastasis [51, 52].
The PI3K/PTEN pathway is responsible for regulating
glucosemetabolism,cellsurvival,adhesion,andmotility[20,
53, 54]. It is found in some thyroid carcinomas (particularly
follicular carcinomas) as well as other types of cancers [55–
60]. Epigenetic methylation leads to silencing of the negativeJournal of Thyroid Research 3
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Figure 1: Molecular pathways of thyroid cancer and their corresponding therapeutic agents.
regulator PTEN gene, thus facilitating increased activity of
the downstream PI3K/Akt pathway [61]. Changes in this
pathway occurred in 31% of benign thyroid adenomas, 24%
of PTCs, 55% of FTCs, and 58% of ATCs according to
one study. The authors concluded that this pathway may be
important in the progression from benign thyroid adenoma
to follicular cancer to ATC [62]. BRAF mutations have
been found along with mutations in PI3K/PTEN pathway
in undiﬀerentiated thyroid carcinoma, perhaps promoting
progression from DTC to undiﬀerentiated thyroid cancer
[15].
3. New Agents for the Treatment of
Thyroid Cancer
3.1. Agents Primarily Targeting Oncogenic Kinases. Given
the increased frequency of BRAF mutations in PTC, a
number of newer therapeutic agents have been developed
that inhibit BRAF. The BRAF inhibitor studied most in
thyroid cancer is sorafenib. Sorafenib (Nexavar, BAY 43-
9006, Bayer) is an oral tyrosine kinase inhibitor which
has been approved by the Food and Drug Administration
for the treatment of advanced renal cell carcinoma and
unresectable hepatocellular carcinoma. It inhibits VEGFR
2/3, RET including RET/PTC1 mutant, c-kit, PDGFR-beta,
and BRAF (including the V600E mutation) [63, 64]. It is a
biaryl compound that locks the mutant constitutively active
kinase in an inactive state. It competitively inhibits ATP
binding in the catalytic domains of both normal and mutant
BRAF. This triggers G1 phase arrest.
None of the four phase 1 trials of sorafenib included
subjects with thyroid cancer, but there is in vitro data in
thyroid cancer cell lines that demonstrated eﬃcacy. The
phase 1 trials established the optimum dosing regimen
as 400mg twice a day [65]. A number of phase II trials
of sorafenib involved advanced or metastatic DTC. These
patients’ tumors demonstrated partial responses in 15–27%
of participants, and stable disease in a little over 34–61%
[66–68]. It should be noted that a recent retrospective
review of thirteen patients with advanced DTC from MD
Anderson demonstrated particular eﬃcacy of this agent
in lung metastasis, while it was less eﬃcacious in bone
metastasis [69]. Given its ability to interfere with RET and
RET/PTC pathways, treatment with sorafenib was attempted
in a phase II trial of MTC. Only a very small portion of
patients achieved a partial response, although stable disease
response rates were comparable to those seen in the DTC
phase II trials [70].
While sorafenib is generally well tolerated with side
eﬀects including rash, diarrhea, hand-foot syndrome, and
fatigue, treatment with sorafenib may be associated with an
increasedriskofcardiactoxicities,withupto40%ofpatients
experiencing EKG changes. Myocardial infarction has also
been reported as a side eﬀect of sorafenib in patients being
treated for renal cell carcinoma [71, 72]. Increased risk for
cutaneoussquamouscellcarcinomashasbeenascribedtothe
entire class of BRAF inhibitors, and sorafenib is no exception
[73].
PLX4032 (RG7204, a Plexxikon drug being codeveloped
with Roche) is a 7-azaindole derivative that is currently in
clinical trials. PLX4032 speciﬁcally inhibits BRAF V600E
to a greater extent than wild-type BRAF [74, 75]. Unlike
sorafenib which only binds to the inactive conformation of
BRAF and keeps it inactive, PLX4032 binds to both the active
form and inactive forms of BRAF. It has been shown to
actively inhibit proliferation of BRAF-mutant-positive cell
lines, particularly in melanoma; thus, most of the clinical
trials have been focused on melanoma [76].
Notably, not all cell lines with BRAF V600E mutations
respond equally to treatment with PLX4032. Although
mutant BRAF V600E has been identiﬁed in ATC, PLX40324 Journal of Thyroid Research
did not lead to apoptosis of the anaplastic thyroid carcinoma
cell line ARO [77]. Diﬀerent melanoma cell lines with BRAF
V600E demonstrate diﬀerential response to PLX4032 as
well; some are highly sensitive while some are essentially
unresponsive to treatment with this agent. These diﬀerences
might be explained by whether the cell line is homozygous
or heterozygous for the BRAF V600E mutation. Variation in
the upregulation of the PI3K/PTEN pathway in response to
treatment with this agent potentially mediates the observed
resistance in nonresponding cell lines [78].
An early clinical trial of PLX4032 demonstrated that
one out of three participants with thyroid cancer achieved
a partial response [79]. Rashes are the most common side
eﬀect of this agent. Again noted is an increase in risk for
development of cutaneous squamous cell carcinomas, likely
owingtoitsanti-BRAFactivity[79].XL281(Exelixis,Bristol-
Meyers-Squibb BMS-908662) is another oral agent similar
to PLX4032 in that it inhibits both wild-type and mutant
BRAF kinases. Phase I clinical trials are ongoing and include
subjects with thyroid carcinoma though early results are not
encouraging [80].
Sunitinib (Sutent, SU11248, Pﬁzer) is a tyrosine kinase
inhibitor aﬀecting VEGFR 1/2/3, RET, RET/PTC1, and
RET/PTC3 [81]. Of DTC and MTC patients enrolled in
a phase II trial of sunitinib receiving 50mg/day, partial
response was observed in 13% of patients with DTC, while
stable disease was the best response in 68% of patients with
DTC. Eighty-three percent of patients with MTC achieved
stable disease [82]. Additionally, there are case reports of
patients with advanced MTC having a dramatic response
to treatment with sunitinib with respect to both serum
calcitonin levels and tumor burden [83]. Patients experience
side eﬀects primarily relating to fatigue, and diarrhea when
treated with sunitinib. Another unique adverse eﬀect of this
agent is palmar-plantar erythrodesia.
Sunitinib can also cause hypothyroidism like many of
the tyrosine kinase inhibitors. The mechanism is thought
to be related to a destructive thyroiditis when administered
for the treatment of renal cell carcinoma [84, 85]. However,
this is unlikely to be the cause of hypothyroidism in thyroid
cancer patients, as they have all presumably undergone
total thyroidectomy. There is other evidence suggesting that
increases in TSH in athyreotic patients are associated with
increased type 3 deiodination and augmented peripheral
thyroid hormone metabolism [86]. Interestingly, some stud-
ies suggest that development of hypothyroidism during
treatment for other cancers other than thyroid cancer may
actually be an encouraging prognostic factor [87, 88].
Heart failure may also be a serious adverse eﬀect
sunitinib, occurring in 2.7% of patients from a retrospective
study of 600 patients at MD Anderson [69]. A diﬀerent
retrospective analysis including 75 patients involved in phase
I and II trials with sunitinib at several centers around the
United States reported an 11% cardiac event rate, and a
decrease in left ventricular ejection fraction of greater than
10% in 47% of included subjects. Half of the included
patients developed hypertension [89]. While the mechanism
ofheartfailureassociatedwithtyrosinekinaseinhibitorsmay
be related to mitochondrial damage, recent studies postulate
that myocyte damage occurs secondary to a lack of target
selectivity of binding to both tyrosine kinases and serine-
threoninekinases[89–91].Oftheclinicallyavailabletyrosine
kinase inhibitors used in one comparison study, sunitinib,
sorafenib, and pazopanib induced the highest degree of
myocyte damage as measured by lactate dehydrogenase
leakage [90].
Vandetanib (Zactima, ZD6474, iPR Pharmaceuticals,
AstraZeneca Pharmaceuticals) is an oral tyrosine kinase
inhibitor that targets VEGFR 2/3, RET, and EGFR [92, 93].
It is a heteroaromatic-substituted anilinoquinazoline. It
speciﬁcally inhibits RET/PTC1 and RET/PTC3 in PTC,
and M918R RET mutations in MEN2B [94, 95]. Recent
investigations into the mechanism of action of vandetanib
in cell culture revealed that the agents ability to block both
RET and EGFR simultaneously can prevent escape from
RET blockade [96] .Ac o m p l e t e dp h a s eI It r i a ld e m o n s t r a t e d
eﬃcacy in metastatic familial MTC [97]; 21% of patients
treated with 300mg/day showed a partial response, while
53% patients had stable disease at 24 weeks. There was a
decrease in levels of calcitonin in most patients. Adverse
eﬀects were signiﬁcant enough to require dose reductions
in several subjects and consisted of diarrhea, severe rash,
fatigue, and QTC prolongation [97].
The vandetanib safety database, which accrues data from
treatmentofmultiplecancertypes,notedapotentialincrease
in other serious entities such as cerebrovascular accidents
and interstitial lung disease [98]. Recent US Food and
Drug Administration review cites concern regarding the
side eﬀect proﬁle of this agent and propose limiting the
indicationstoprogressivesymptomaticdisease[98].Another
recently published study of subjects with locally advanced or
metastatic hereditary MTC administered only 100 mg/day of
the drug with nearly similar response rates compared to the
above study, and was somewhat better tolerated regarding
side eﬀects [99]. Other phase II trials for familial MTC and
DTCareunderway,asarephaseIIItrialsformetastaticMTC.
Based on the above mentioned trials as well as other recent
data, in April 2011, the US Food and Drug Administration
approved vandetanib for use in late-stage MTC. This is the
ﬁrst medication approved by the FDA for the treatment of
MTC [100].
Imatinib Mesylate (STI571, Gleevec, Novartis) is an
oral tyrosine kinase inhibitor (TKI) that suppresses c-ABL
mutation, c-KIT, and inhibits RET autophosphorylation
[101]. It was ﬁrst utilized in the 1990s for treatment of
BCR/ABL-positive leukemias. In anaplastic thyroid cancer
cell lines (FRO and ARO), it caused growth inhibition,
but did not inhibit growth in papillary thyroid cancer cell
lines [102, 103]. Two small phase II trials of patients with
MTC showed only a small percentage of subjects achieving a
stable disease as their best tumor response [104, 105]. These
patientsweretreatedwith600mgdailyofimatinib.Overhalf
of the patients were noted to have profound hypothyroidism
and required signiﬁcant increases in their need for thyroid
hormone.
New agents are also on the horizon, particularly in RET-
mutant MTC. Withaferin A (WA) is a novel compound
which appears eﬀective against MTC cell proliferation inJournal of Thyroid Research 5
culture. WA inhibits both activation and phosphorylation
of RET as well as total RET expression. The investigators
recently published evidence of its eﬃcacy in a murine model
of MTC. Treatment with WA resulted in 80% regression of
tumor volume in the treated animals with a corresponding
signiﬁcant decrease in calcitonin levels. Additionally, all the
treated animals were alive at 6 weeks, while essentially all the
control animals died by this point in time [106].
3.2. Agents Primarily Targeting Signaling Kinases. Pazopanib
(Votrient, GlaxoSmithKline, GW786034) is a second-gener-
ation oral small molecule kinase inhibitor that targets
VEGFR-1, 2, and 3, as well as alpha and beta PDGFR [107].
There is new data from studies of breast cancer indicating
that it also targets multiple forms of Raf, though it likely
does not aﬀect the common BRAF V600E mutant [108].
It is approved for use in renal cell carcinoma and is likely
eﬀective in other forms of cancer including ovarian cancer,
and nonsmall cell lung carcinoma [109–111].
A phase II study completed in early 2009 of thyroid
cancer patients led by the Mayo Clinic demonstrated a
conﬁrmed partial response rate by RECIST criteria in
49% of enrolled subjects (18 patients). There were no
complete responses [112]. Starting dose was 800mg per day.
Patients able to tolerate maximum doses of the medication
signiﬁcantly decreased their tumor size as compared to those
patients unable to tolerate maximum doses of the agent.
Although not statistically signiﬁcant, the subset of patients
with FTC attained a partial response more frequently than
subjects with PTC. Forty-three percent (43%) required dose
reductions, owing most frequently to fatigue, skin and hair
hypopigmentation, diarrhea, and nausea. Nearly 66% of
patients doubled their TSH concentrations. Also of note,
three patients (8%) developed grade 3 lower gastrointestinal
hemorrhage, which according to the authors is similar to the
rate noted in trials with Sorafenib [112].
Motesanib (AMG706, Amgen) is an oral tyrosine-kinase
inhibitor that inhibits autophosphorylation of RET and
also targets VEGFR 1, 2, and 3, PDGFR, and c-KIT. It
demonstrates both direct antitumor and antiangiogenic
properties[113].Phase1trialswereencouragingwith3DTC
patients registering a partial response [114]. A subsequent
phaseIItrialadministering 125mg/daytopatientswithDTC
demonstrated a partial response in 14% of patients, while
35% of patients had stable disease after 48 weeks [115]. A
separatearmofthisstudyexaminedacohortofpatients with
advanced, progressive, symptomatic, or metastatic MTC.
In this MTC cohort, 2% of patients showed an objective
response, 81% maintained stable disease, and an overall 76%
of patients showed decrease in the size of their target lesions
[116].Motesanibwasgenerallywelltoleratedinbothcohorts
with fatigue, nausea, diarrhea, and hypertension comprising
t h em a j o r i t yo fa d v e r s es i d ee ﬀects. As a result of treatment
with motesanib, greater than 60% of patients experienced
a TSH elevation out of the desired therapeutic range at
some time during the study [116]. A recent study of both
DTC and MTC revealed that a decrease in soluble VEGFR-2
and a concurrent increase in placental growth factor (PlGF)
during the course of treatment with motesanib predicted
which patients would respond to treatment with this agent
[117].
Axitinib (AG-013736) inhibits VEGFR more speciﬁcally
than the agents discussed above. A phase I study included
patients with thyroid cancer though none demonstrated
partial responses [118]. A phase II study using a dose of 5mg
orallytwotimesperdaynotedpartialresponsesin31%ofthe
patientswithDTCandin18%ofthepatientswithMTC.Side
eﬀects included fatigue, stomatitis, and hypertension [119].
Further trials are ongoing.
XL 184 (BMS-907351) inhibits VEGF 1 and 2, C-MET,
RET, c-kit, fms-related tyrosine kinase 3 (FLT3), and TIE-2.
A unique aspect of this agent is its activity against hepatocyte
growth factor (HGF) and C-MET, both of which are overex-
p r e s s e di nP T C[ 120]. A phase 1 trial was promising; 55% of
36 patients MTC demonstrated a partial response, and 84%
overall had stable disease [121]. Interestingly, patients both
withandwithoutRETmutationsresponded.AphaseIIItrial
exploring XL 184 in MTC is currently underway.
Other recently evaluated novel agents include pyra-
zolopyrimidine derivatives like CLM3 and CLM29, which
also appear to be widely eﬀective against cytoplasmic and
receptor ATP competitive tyrosine kinases including RET,
EGFR, VEGFR, and angiogenesis pathways. These agents
are unique because they induce apoptosis and decrease
tumor volume in murine models of dediﬀerentiated PTC,
irrespective of BRAFV600E mutation [122].
4. Conclusion
Recent increased incidence of thyroid cancer is associated
with a rise in the number of patients with metastatic disease
and tumors that are resistant to the eﬀect of radioiodine.
Presently, there are no consensus guidelines about safe and
eﬀective methods to treat advanced-stage thyroid cancers.
However, the recent elucidation of the pathogenesis of
thyroid cancer has facilitated the development of new
targeted agents intended to have activity against speciﬁc
biochemical and oncologic pathways. Many of these newer
agents being developed and tested are kinase inhibitors that
s h o wap r o m i s ef o ri m p r o v edtr e a tm e n to fad v a n c edD T C ,a s
well as MTC.
In general, options for the chemotherapeutic treatment
of advanced-stage thyroid cancers remain limited. The most
promising agents display activity against VEGFR, including
pazopanib, motesanib, sorafenib, sunitinib, and vandetanib.
There is structural similarity between VEGFR and RET
kinases, and cross-activity likely occurs perhaps increasing
the eﬃcacy of these agents. Interestingly, axitinib (a tyrosine
kinase inhibitor that more speciﬁcally targets VEGFR)
garnered similar promising tumor responses to the above
noted multitargeted kinase inhibitors [119]. In addition,
the eﬀective targeted kinase inhibitors not only demonstrate
speciﬁc activity against VEGFR, but also exhibit activity
against a wide array of cellular pathways.
Perhaps owing to their wide ranging cellular targets,
there are also numerous concerning side eﬀects of these
multitargeted kinase inhibitors. Several trials of the above
listed agents reported a signiﬁcant percentage of patients6 Journal of Thyroid Research
requiring a dose reduction during the study period for
general tolerability. The most concerning adverse eﬀects are
increases in the incidence of cardiomyopathy and associ-
ated hypertension and stroke. Additionally, minor-to-severe
bleeding (often in the form of gastrointestinal bleeding)
should not be overlooked. Trials of motesanib and sunitinib
noted increasing TSH values during the course of treatment,
placing patients at risk for being on subtherapeutic doses of
suppressive thyroid hormone for a period of time.
Other targeted kinase agents have been shown less
eﬀective than previously hoped. Imatinib does not appear
to be a candidate for further study in MTC, nor does
geﬁtinib which was not discussed in detail because a phase
II trial did not demonstrate any partial responses [123].
Agents speciﬁcally targeting the BRAF pathway and BRAF
V600E are in earlier stages of clinical trials; however, stable
disease appears to be the best response achieved in this
class of agents, including PLX4032 as well as XL281. The
more speciﬁc BRAF inhibitors also have concerning side
eﬀects, including an increased incidence of squamous cell
neoplasms.
Overall, options for targeted therapy of patients with
advanced thyroid cancer remain limited. While these agents
may improve radiographic tumor response, change in sur-
vival is unclear. Most trials have demonstrated that only
small percentages of patients achieved partial responses.
There has been a lack of complete responses [124]. Current
expert opinion advises that these agents be used only in a
speciﬁc subset of patients. They should be administered only
to patients with rapidly progressive radioiodine refractory
metastatic disease. Locally recurrent, unresectable cancer
which is unresponsive to radiation may also be considered
appropriate for treatment [125].
Other lines of research must be pursued including
immunotherapy with vaccines and interferon adminis-
tration, as well as eﬀorts to induce rediﬀerentiation of
tumor cells to take up radioiodine with histone deacetylase
inhibitors Romidepsin and Vorinostat, for example [126–
131]. Another area that warrants further investigation is
the exploration of biomarkers that may be able to predict
response to a given agent, which may help tailor treatment
to an individual. Additionally, both in vivo and in vitro
chemosensitivity testing is becoming more common, and
is currently available in several clinical trials. These tests
appear to be most useful in terms of negative predictability,
meaning a treatment is very likely to be unsuccessful in
vivo if it is unsuccessful in vitro. Unfortunately the positive
predictability of such tests is not as robust. There are many
diverse challenges to be addressed before chemosensitivity
becomes routine [122, 132]. Promising new studies are being
performed investigating combinations of tyrosine kinase
inhibitors with other conventional modalities of treatment,
like radiation [133]. Much new data is required before such
agents are oﬀered routinely for the treatment of advanced or
dediﬀerentiated thyroid cancer.
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